FDA Commissioner Marty Makary is expected to be fired from his role, according to multiple media reports. The White House plans haven’t been finalized and could still change — but the reporting is coming from multiple outlets, not one.
That’s a meaningful distinction. When a single reporter runs a personnel scoop, it can be a trial balloon. When multiple outlets confirm it simultaneously, the machinery is usually already moving.
Makary, appointed by Trump, leads an agency responsible for drug approvals, device clearances, and the food safety framework that covers most of what Americans eat and drink. Commissioner-level exits create a vacuum that acting officials can’t fully fill: an acting FDA commissioner can manage the day-to-day but can’t deliver the kind of high-profile, politically durable decisions a Senate-confirmed leader can.
What the reports don’t say: the reason behind the move, who would replace Makary, or a timeline. Those gaps are going to make the next few weeks uncomfortable for anyone waiting on an FDA decision.
The pharmaceutical sector and medical device industry don’t tolerate uncertainty at the top of the FDA well. For now, Makary remains in his role.
— Sarah Chen